9 recruiting, 5 not yet recruiting, 4 completed, 3 active not recruiting. 9 Phase 1, 8 Phase 2, 3 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Myelofibrosis (MF): new trials by email Literature Review of Myelofibrosis (MF) trials Research Report on Myelofibrosis (MF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Pacritinib Effectiveness in Real-world Settings Not applicable- observational study - Myelofibrosis (MF) | Recruiting | Swedish Orphan Biovitrum | 60 | 2026-08-13 | 2026-10-21 | |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Not yet recruiting | Eilean Therapeutics | 60 | 2026-05-15 | 2026-04-14 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-29 |
| Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis Gecacitinib (also known as Jaktinib) - Myelofibrosis (MF), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 39 | 2026-03-16 | 2026-03-13 |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) Axatilimab (SNDX-6352), Ruxolitinib - Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 66 | 2026-01-02 | 2026-10-09 |
| Momelotinib Effectiveness in Myelofibrosis Myelofibrosis (MF) | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 93 | 2026-01-02 | 2025-11-25 | |
| A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors Roginolisib - Myelofibrosis (MF) | Phase 1 / Phase 2 | Recruiting | iOnctura | 26 | 2025-11-17 | 2026-06-23 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms Myelofibrosis (MF), Polycythemia Vera | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1190 | 2025-02-17 | 2026-10-07 | |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept Diagnosis of MPN subtypes - Myelofibrosis (MF) | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 265 | 2023-09-05 | 2026-02-18 |
| Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms Essential Thrombocythemia (ET), Myelofibrosis (MF) | Active not recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 110 | 2022-02-15 | 2025-01-29 | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Mivebresib, Navitoclax, Ruxolitinib - Myelofibrosis (MF) | Phase 1 | Terminated | AbbVie | 1 | 2021-03-17 | 2023-08-29 |
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis ABBV-744, Navitoclax, Ruxolitinib - Myelofibrosis (MF) | Phase 1 | Active not recruiting | AbbVie | 21 | 2020-11-11 | 2025-07-16 |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Placebo for Navitoclax, Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 3 | Completed | AbbVie | 252 | 2020-09-29 | 2026-03-23 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Navitoclax, Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis (MF) | Phase 3 | Active not recruiting | AbbVie | 330 | 2020-08-31 | 2026-01-09 |
| A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 2 | Completed | AbbVie | 191 | 2017-10-31 | 2026-01-20 |
Showing 20 of 23. Sign in to see all of them.
Primary Myelofibrosis (23) · Polycythemia Vera (7) · Myeloproliferative Disorders (5) · Neoplasms (5) · Thrombocythemia, Essential (5) · Myelodysplastic Syndromes (3) · Hematologic Neoplasms (2) · Leukemia, Myelomonocytic, Chronic (2) · Anemia, Aplastic (1) · Blast Crisis (1) · Bone Marrow Neoplasms (1) · Disease Progression (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
Bone Marrow Diseases (23) · Hematologic Diseases (23) · Hemic and Lymphatic Diseases (23) · Myeloproliferative Disorders (18) · Neoplasms (10) · Neoplasms by Site (8) · Bone Marrow Neoplasms (6) · Hematologic Neoplasms (6) · Blood Coagulation Disorders (5) · Blood Platelet Disorders (5) · Hemorrhagic Disorders (5) · Thrombocytosis (5) · Neoplasms by Histologic Type (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3)
ruxolitinib (7) · navitoclax (5) · ABBV-744 (1) · Endoscopy, Digestive System (1) · KB004 (1) · Methotrexate (1) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (1) · Tacrolimus (1) · axatilimab (1) · luspatercept (1) · mivebresib (1)
AbbVie (5) · Azienda Ospedaliero-Universitaria di Parma (1) · Eilean Therapeutics (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Humanigen, Inc. (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · MPN Research Foundation (1) · Nanfang Hospital, Southern Medical University (1) · Prelude Therapeutics Incorporated (1) · SWOG Cancer Research Network (1) · Singapore General Hospital (1)
United States (12) · Italy (9) · Australia (6) · Spain (6) · South Korea (5) · Canada (4) · Israel (4) · Japan (4) · United Kingdom (4) · Bulgaria (3) · Croatia (3) · France (3) · Greece (3) · Hungary (3) · South Africa (3)
Alexander Coltoff, MD (1) · Francesco Passamonti (1) · John Mascarenhas (1) · Lucia Catani, MD (1) · Michael Lahn, Dr (1) · Morgan Lam (1) · Naveen Pemmaraju, MD (1) · Qifa Liu (1) · Raajit Rampal, MD, PhD (1) · Raman Garcha, MD (1) · Vanessa Kennedy, MD (1) · Vikas Gupta, MD, FRCP (1)
PMID 42842696, PMID 20424252, PMID 21742281, PMID 27736729, PMID 28096091, PMID 29895954, PMID 34002031, PMID 35180010, PMID 35576960, PMID 37311468, PMID 40454409, PMID 41843794, PMID 41846295
2017 (1), 2023 (1)